Obagi Medical Partners with Platinum Dermatology for Real-World Evidence on saypha MagIQ Injectables
Event summary
- Obagi Medical, part of Waldencast plc (NASDAQ: WALD), has partnered with Platinum Dermatology Partners for the ALOHA Program to gather real-world evidence on its saypha MagIQ hyaluronic acid injectable.
- Platinum will evaluate the product across multiple practices and present initial findings at its September 2026 summit in Dallas.
- saypha MagIQ uses MACRO Core Technology for stable hyaluronic acid matrix, designed for natural-looking results with high usable HA content upon injection.
The big picture
This collaboration underscores a broader industry shift toward leveraging real-world evidence to validate aesthetic treatments, particularly as regulatory scrutiny and consumer demand for transparency increase. With Platinum’s extensive network of dermatology providers, the partnership could accelerate saypha MagIQ’s market penetration while reinforcing Obagi Medical’s position as an innovator in physician-dispensed skincare solutions.
What we're watching
- Clinical Validation
- Whether the ALOHA Program can demonstrate real-world efficacy that aligns with clinical trial data, potentially setting a new standard for aesthetic injectables.
- Market Differentiation
- How Obagi Medical’s focus on evidence-based product development will position saypha MagIQ against competitors in the growing injectable aesthetics market.
- Scalability
- The pace at which Platinum Dermatology can integrate and scale the ALOHA Program across its 120+ locations, influencing adoption rates and revenue growth.
Related topics